Multiple Myeloma Clinical Trials in Detroit, Michigan

13 studies are recruiting for multiple myeloma in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

   This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to pa…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute., Detroit, Michigan

   Locations

   34 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04910568 on ClinicalTrials.gov

2. A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

   Multiple myeloma is a cancer of the plasma cells in the bone marrow. The main aim of this study is to learn how well the Immune Globulin Infusion (human), 10 percentage (%) (IGI, 10%) can help prevent infections in participants with multiple myeloma receiving B-cell maturation antigen (BCMA) x clus…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Locations

   56 in total

   Run by

   Takeda

   See if you can join NCT06980480 on ClinicalTrials.gov

3. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Henry Ford Health Saint John Hospital, Detroit, Michigan

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

4. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

   The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Barbara Ann Karmanos Cancer Institute, Detroit, Michigan

   Locations

   50 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05201781 on ClinicalTrials.gov

5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

   The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit, Michigan

   Locations

   270 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05552222 on ClinicalTrials.gov

6. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   151 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

7. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

   This is a Phase 2, open-label, single-arm, multicenter study to assess the antimyeloma activity and further characterize the safety, tolerability, PK, and PD of cemsidomide in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (r/r MM).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   21 in total

   Run by

   C4 Therapeutics, Inc.

   See if you can join NCT07284758 on ClinicalTrials.gov

8. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

   This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that r…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   42 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT05137054 on ClinicalTrials.gov

9. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

   This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit, Michigan

   Locations

   33 in total

   Run by

   Pfizer

   See if you can join NCT06057402 on ClinicalTrials.gov

10. Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma

    The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant [ASCT]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC) Daratumumab. The ma…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Karmanos Cancer Institute, Detroit, Michigan

    Locations

    2 in total

    Run by

    Barbara Ann Karmanos Cancer Institute

    See if you can join NCT06107738 on ClinicalTrials.gov

11. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

    This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Karmanos Cancer Institute, Detroit, Michigan

    Locations

    32 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT05828511 on ClinicalTrials.gov

12. A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

    The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    GSK Investigational Site, Detroit, Michigan

    Locations

    181 in total

    Run by

    GlaxoSmithKline

    See if you can join NCT06679101 on ClinicalTrials.gov

13. Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

    The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research que…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Barbara Ann Karmanos Cancer Center, Detroit, Michigan

    Locations

    40 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT03761108 on ClinicalTrials.gov